PT - JOURNAL ARTICLE AU - Sudarshan Reddy Lokireddy AU - Sridhar Rao Kunchala AU - Ranga Pratyusha Godavarthy AU - Venkata Sri Krishna Kona AU - Laxmaiah Avula AU - Rakesh Kumar Mishra AU - Madhusudhana Rao Nalam TI - Rapid, sensitive and high-throughput screening method for detection of SARS-CoV-2 antibodies by bio layer interferometry AID - 10.1101/2020.08.15.20175851 DP - 2020 Jan 01 TA - medRxiv PG - 2020.08.15.20175851 4099 - http://medrxiv.org/content/early/2020/08/17/2020.08.15.20175851.short 4100 - http://medrxiv.org/content/early/2020/08/17/2020.08.15.20175851.full AB - Present pandemic scenario, there exists an unmet global need for the development of a rapid and sensitive method for the detection of SARS-CoV-2 infection. The available options for identification of SARS-CoV-2 infection are detection of viral RNA by qRT-PCR, Antigen or Antibody testing by serological methods. Even though many kits available commercially but none of them are rapid, sensitive and high throughput. ‘OnCovid total antibody assay’ is a diagnostic method developed by us uses the principle of bio-layer Interferometry to detect IgM, IgA and IgG antibodies against SARS-CoV-2 antigens. This method overcomes many of the limitations normally faced in antibody detection by other methods and offers a superior platform for a rapid, sensitive and specific detection of SARS-CoV-2 infection. The test is economical, and the results can be obtained in as short as 30 seconds per test. In addition to its standalone use in early diagnosis of SARS-CoV-2, ‘OnCovid total antibody assay’ can be used to therapeutic monitoring of antiviral therapies used in clinical management and to estimate the antibody titers during convalescent plasma donation.Competing Interest StatementAuthor declare no conflict of interest. OnCovid, AcceTT are trademarks of Oncosimis Biotech Private Limited. SRL, SRK, RPG, and VSKK employees of Oncosimis Biotech Private Limited.Funding StatementThis technology has been selected by C-CAMP COVID-19 innovations deployment accelerator (C-CIDA) and partially funded and supported by CSIR-CCMB, Hyderabad under Deploying COVID-19 Innovation. Oncosimis Biotech Private Limited also grateful for DBT, BIRAC for providing funding for AcceTT platform for increased expression of recombinant protein in mammalian system.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All blood samples were collected by health professionals by abiding to human ethical approvals by Centre for Cellular and Molecular Biology (CCMB), ICMR-National Institute of Nutrition (NIN), Hyderabad, TS, India.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll raw data files shall be available upon request.